In biotech, CEO insider buys are common and not very predictive. The real signal comes from the rest of the management team, especially the CFO. CFOs are typically more bearish and financially disciplined, so their decision to buy company stock is a particularly strong vote of confidence.

Identifying a stock trading below its intrinsic value is only the first step. To avoid "value traps" (stocks that stay cheap forever), investors must also identify a specific catalyst that will unlock its value over a reasonable timeframe, typically 2-4 years.

Insider buying in biotech isn't just a short-term trading signal around an event. The quantitative analysis shows its predictive power lasts for months after the transaction. This implies insiders are buying based on a durable, fundamental belief in the company's science and trajectory, not just upcoming news.

When screening for insider activity, purchases by the Chief Financial Officer (CFO) may warrant special attention. Academic research indicates that CFOs, perhaps due to deeper financial acumen and risk awareness, have historically achieved better investment results on their personal stock purchases compared to CEOs.

Rather than passively holding a stock, the "buy and optimize" strategy involves actively managing its weighting in a portfolio. As a stock becomes more expensive relative to its intrinsic value, the position is trimmed, and when it gets cheaper, it is increased, creating an additional layer of return.

Barclays' research shows that the best investment performance comes from combining fundamental analysts with systematic signals. The key is to filter out trades where the two perspectives diverge, as this method is exceptionally effective at eliminating potential losing investments and generating alpha.

A tender offer, where a company buys a large block of its stock in a set price range, signals higher conviction than a typical buyback program. It forces management to put a stake in the ground, indicating they believe the shares are significantly undervalued at a specific price.

To achieve excess returns, one must buy assets for less than they are worth. This requires finding a seller willing to transact at that low price—someone making a mistake. These mistakes arise from emotional biases, forced selling due to mandates, or misunderstanding complexity, creating bargain opportunities for disciplined, “second-level” thinkers.

To sharpen the insider buying signal, the firm analyzes proxy statements to exclude purchases made solely to satisfy board-mandated ownership requirements. Only voluntary, 'free will' buys are considered true indicators of an insider's belief that the stock is undervalued.